Abstract
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of cells that inhibit anti-tumor immunity through a variety of mechanisms. Malignant gliomas are heavily infiltrated by myeloid cells, some of which appear to share biological functions of MDSCs. Our data with mouse de novo gliomas indicate critical roles of these cells in glioma development. This review summarizes the current understanding of MDSC biology in gliomas and discusses therapeutic interventions that can safely reverse the suppressive effects of MDSCs. The insight gained from these findings may lead to the development of novel immunotherapeutic strategies for gliomas.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Arginase / genetics
-
Arginase / immunology
-
CD11b Antigen / genetics
-
CD11b Antigen / immunology
-
Cyclooxygenase 2 / genetics
-
Cyclooxygenase 2 / immunology
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Glioma / immunology
-
Glioma / metabolism
-
Glioma / pathology*
-
Glioma / therapy*
-
Humans
-
Immune Tolerance
-
Immunotherapy
-
Interleukin-4 Receptor alpha Subunit / genetics
-
Interleukin-4 Receptor alpha Subunit / immunology
-
Mice
-
Myeloid Progenitor Cells / drug effects*
-
Myeloid Progenitor Cells / immunology
-
Myeloid Progenitor Cells / pathology
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
T-Lymphocytes / pathology
-
Tumor Escape
Substances
-
Antibodies, Monoclonal
-
CD11b Antigen
-
Enzyme Inhibitors
-
IL4R protein, human
-
ITGAM protein, human
-
Interleukin-4 Receptor alpha Subunit
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
ARG1 protein, human
-
Arginase